MorphoSys AG (NASDAQ:MOR)
| 8.48 Delayed Data As of Jan 14 |  -0.37 / -4.18%Today’s Change | 8.30 Today|||52-Week Range 30.75 | -9.98% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $1.2B |
Company Description
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery segments. The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.
Contact Information
MorphoSys AG Semmelweisstrasse 7 Planegg Bayern (bavaria) 82152 |
Employees
Shareholders
| Other institutional | 1.47% |
| Mutual fund holders | 0.37% |
| Individual stakeholders | -- |
Top Executives
| Jean-Paul Kress | CEO & Chairman-Management Board |
| Sung H. Lee | Chief Financial Officer |
| Malte Peters | Chief Research & Development Officer |
| Armin Weidmann | Head-Compliance & Quality Assurance |
| Charlotte Lohmann | Senior Vice President & General Counsel |
